| Filed On | Filing |
|---|---|
| 13 Nov 2026 | SCHEDULE 13G/A |
| 12 Nov 2026 | S-3ASR |
| 12 Nov 2026 | 10-Q |
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition; Other Events
ABS-201™ HEADLINE™ trial progressing on track; 13-week interim proof-of-concept data for pattern hair loss (PHL) anticipated next month |
| 30 Oct 2026 |
Form 4: McClain Sean, Director
Gave up 79,860 shares to cover exercise price or tax ($966K) |
| 27 Oct 2026 | SCHEDULE 13G/A |
| 14 Oct 2026 |
Form 4: McClain Sean, Director
Gave up 23,293 shares to cover exercise price or tax ($237K) |
| 14 Oct 2026 |
Form 4: Bedrick Todd, SVP, CAO
Gave up 22,325 shares to cover exercise price or tax ($227K) |
| 14 Oct 2026 |
Form 4: Jonasson Zachariah, CFO / CBO
Gave up 387 shares to cover exercise price or tax ($3.93K) |
| 01 Sep 2026 |
Form 4: Jonasson Zachariah, CFO / CBO
Gave up 8,320 shares to cover exercise price or tax ($72.5K) |
| 11 Aug 2026 | 10-Q |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition; Other Events
Announced positive interim Phase 1 data from the HEADLINE™ trial of ABS-201 |
| 07 Aug 2026 |
Form 4: Somaratne Ransi Mudalinayake, CMO, Head of R&D
Granted 650,000 Stock Option (right to buy) · Granted 383,000 Stock Option (right to buy) |
| 07 Aug 2026 |
Form 3: Somaratne Ransi Mudalinayake, CMO, Head of R&D
No securities owned |
| 06 Jul 2026 |
Form 4: Szela Mary T, Director
Bought 12,900 shares ($149K) |
| 26 Jun 2026 |
Form 4: McClain Sean, Director
Gave up 59,896 shares to cover exercise price or tax ($603K) |
| 24 Jun 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
Absci Corporation, a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an ag... |
| 24 Jun 2026 | 424B5 |
| 24 Jun 2026 |
8-K: Other Events
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) |
| 15 Jun 2026 |
Form 4/A: Szela Mary T, Director
Received 8,400 shares as a grant or award · Granted 33,200 Stock Option (right to buy) |
Loading...